HomeBUSINESS
BUSINESS

AbbVie’s 8-Week Hep C Therapy Filed in Japan
(Feb.15.2017)

AbbVie filed a new drug application in Japan on February 14 for its pan-genotypic interferon-free hepatitis C regimen glecaprevir/pibrentasvir (G/P), which, if approved, will offer an eight-week treatment option for genotype 1 and 2 hepatitis C - the markets now dominated by Gilead Sciences’ drugs ...
(LOG IN FOR FULL STORY)

News Calendar